Manufacturer
BRISTOL-MYERS SQUIBB MANUFACTURING COMPANY
Contents
Apixaban
Indication
DVT & pulmonary embolism (PE). Prevention of stroke & systemic embolism in adult patients w/ non-valvular atrial fibrillation (NVAF), w/ ≥1 risk factor [eg, prior stroke or transient ischaemic attack, age ≥75 yr, HTN, DM, symptomatic heart failure (NYHA class ≥II)]. Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of recurrent DVT & PE in adult patients.
Instruction
May be taken with or without food: May be crushed & suspended in water/D5W/apple juice or mixed w/ apple puree. Take mixt immediately or w/in 4 hr.
Drug interaction
Increased plasma conc w/ azole antimycotics (eg, ketoconazole, itraconazole, voriconazole & posaconazole), HIV-PIs (eg, ritonavir), diltiazem, naproxen, amiodarone, verapamil, quinidine. Decreased plasma conc w/ rifampicin, phenytoin, carbamazepine, phenobarb or St. John's wort. Increased bleeding risk w/ other anticoagulants, platelet aggregation inhibitors & NSAIDs including ASA. Serious bleeding risk w/ thrombolytic agents, GPIIb/IIIa receptor antagonists, thienopyridines (eg, clopidogrel), dipyridamole, dextran & sulfinpyrazone. Reduced exposure w/ activated charcoal.
Malaysia
